Infliximab for the treatment of rheumatoid arthritis
34 results
1 - 34
Infliximab for the treatment of rheumatoid arthritis
Infliximab for rheumatoid arthritis - Rheumatoid arthritis
- Biologics for rheumatoid arthritis: an overview of Cochrane reviews
- Biologic interventions for fatigue in rheumatoid arthritis
- Anakinra for rheumatoid arthritis: Cochrane systematic review
- Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta‐analysis
- Combination therapy in rheumatoid arthritis
- Anakinra for rheumatoid arthritis
- Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
- Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease‐modifying anti‐rheumatic drugs: a systematic review and network meta‐analysis
- Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta‐analysis
- Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis): Cochrane systematic review
- Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity
- Chronic diseases and pregnancy
- Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis
- Methotrexate for induction of remission in refractory Crohn's disease: Cochrane systematic review
- Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)
- Adverse effects of biologics: a network meta‐analysis and Cochrane overview